PMID

Data

Article Title

Organization

Discovery and Preclinical Evaluation of BMS-711939, an Oxybenzylglycine Based PPARa Selective Agonist.

Bristol-Myers Squibb

Discovery of novel indazole derivatives as dual angiotensin II antagonists and partial PPAR¿ agonists.

Glaxosmithkline

Structure-activity studies on 1,3-dioxane-2-carboxylic acid derivatives, a novel class of subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

Nippon Shinyaku

Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

Nippon Shinyaku

Conversion of human-selective PPARalpha agonists to human/mouse dual agonists: a molecular modeling analysis.

Eli Lilly

O-arylmandelic acids as highly selective human PPAR alpha/gamma agonists.

Merck Research Laboratories

Discovery of cyclic amine-substituted benzoic acids as PPARa agonists.

Kyorin Pharmaceutical

Synthesis and pharmacological evaluation of novel benzoylazole-based PPARa/κ activators.

Dainippon Sumitomo Pharma

Development of a new class of benzoylpyrrole-based PPARa/¿ activators.

Dainippon Sumitomo Pharma

A stereo-controlled synthesis of 2,4-dimethyl-4-hydroxy-16-phenylhexadecanoic acid 1,4-lactone and its PPAR activities.

Seoul National University

Glycine amides as PPARalpha agonists.

Bayer-Schering Pharma

Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).

Bristol-Myers Squibb

Synthesis and biological activities of novel indole derivatives as potent and selective PPARgamma modulators.

Glaxosmithkline

Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

Merck Research Laboratories

Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma a

Merck Research Laboratories

Aleglitazar, a new, potent, and balanced dual PPARalpha/gamma agonist for the treatment of type II diabetes.

F. Hoffmann-La Roche

The discovery of equipotent PPARalpha/gamma dual activators.

Glaxosmithkline

Design, synthesis and evaluation of trifluoromethane sulfonamide derivatives as new potent and selective peroxisome proliferator-activated receptor alpha agonists.

Glaxosmithkline

Indanylacetic acid derivatives carrying aryl-pyridyl and aryl-pyrimidinyl tail groups--new classes of PPAR gamma/delta and PPAR alpha/gamma/delta agonists.

Bayer Pharmaceuticals

Design and synthesis of substituted phenylpropanoic acid derivatives as human peroxisome proliferator-activated receptor alpha/delta dual agonists.

University of Tokyo

Synthesis, biological evaluation, and molecular modeling investigation of new chiral fibrates with PPARalpha and PPARgamma agonist activity.

Università

Discovery of a novel series of peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes and dyslipidemia.

Merck Research Laboratories

Design, Synthesis, and Biological Evaluation of Triazolone Derivatives as Potent PPAR?/? Dual Agonists for the Treatment of Nonalcoholic Steatohepatitis.

China Pharmaceutical University

(2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.

Merck Research Laboratories

Discovery of novel modulators for the PPAR? (peroxisome proliferator activated receptor ?): Potential therapies for nonalcoholic fatty liver disease.

City of Hope National Medical Center

Novel selective small molecule agonists for peroxisome proliferator-activated receptor delta (PPARdelta)--synthesis and biological activity.

Glaxosmithkline

Identification of a series of PPAR gamma/delta dual agonists via solid-phase parallel synthesis.

Glaxosmithkline

Identification of a subtype selective human PPARalpha agonist through parallel-array synthesis.

Glaxosmithkline

The PPARs: from orphan receptors to drug discovery.

Glaxo Wellcome Research & Development

A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

Glaxo Wellcome Research & Development

Structural development of 1H-pyrazolo-[3,4-b]pyridine-4-carboxylic acid derivatives as human peroxisome proliferator-activated receptor alpha (PPAR?)-selective agonists.

Okayama University

The Race to Bash NASH: Emerging Targets and Drug Development in a Complex Liver Disease.

Terns Pharmaceuticals

Discovery of potent and selective PPAR?/? dual antagonists and initial biological studies.

Inception Sciences

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones.

Glaxo Wellcome Research and Development

Design, Synthesis, and Evaluation of a Novel Series of Indole Sulfonamide Peroxisome Proliferator Activated Receptor (PPAR)?/?/? Triple Activators: Discovery of Lanifibranor, a New Antifibrotic Clinical Candidate.

Inventiva

Switching subtype-selectivity: Fragment replacement strategy affords novel class of peroxisome proliferator-activated receptor?/? (PPAR?/?) dual agonists.

The University of Tokyo

Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

Virginia Commonwealth University

The design, synthesis and potential utility of fluorescence probes that target DFG-out conformation of p38alpha for high throughput screening binding assay.

Pfizer